Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Inventory (2019 - 2025)

Historic Inventory for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $16.2 million.

  • Pulmonx's Inventory fell 419.25% to $16.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year decrease of 419.25%. This contributed to the annual value of $16.9 million for FY2024, which is 102.73% up from last year.
  • Pulmonx's Inventory amounted to $16.2 million in Q3 2025, which was down 419.25% from $16.2 million recorded in Q2 2025.
  • Over the past 5 years, Pulmonx's Inventory peaked at $19.2 million during Q2 2022, and registered a low of $11.9 million during Q1 2021.
  • For the 5-year period, Pulmonx's Inventory averaged around $16.1 million, with its median value being $16.2 million (2025).
  • Per our database at Business Quant, Pulmonx's Inventory skyrocketed by 6133.72% in 2021 and then tumbled by 1861.34% in 2023.
  • Pulmonx's Inventory (Quarter) stood at $16.3 million in 2021, then decreased by 10.57% to $14.6 million in 2022, then increased by 14.96% to $16.7 million in 2023, then rose by 1.03% to $16.9 million in 2024, then fell by 3.94% to $16.2 million in 2025.
  • Its Inventory stands at $16.2 million for Q3 2025, versus $16.2 million for Q2 2025 and $16.8 million for Q1 2025.